- Home
- ACAD vs PHI Comparison
ACAD vs PHI Comparison
Compare ACAD & PHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- PHI
- Stock Information
- Founded
- ACAD 1993
- PHI 1928
- Country
- ACAD United States
- PHI Philippines
- Employees
- ACAD N/A
- PHI N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- PHI Telecommunications Equipment
- Sector
- ACAD Health Care
- PHI Telecommunications
- Exchange
- ACAD Nasdaq
- PHI Nasdaq
- Market Cap
- ACAD 4.3B
- PHI 4.1B
- IPO Year
- ACAD 2004
- PHI 1953
- Fundamental
- Price
- ACAD $21.31
- PHI N/A
- Analyst Decision
- ACAD Buy
- PHI Hold
- Analyst Count
- ACAD 21
- PHI 1
- Target Price
- ACAD $29.25
- PHI N/A
- AVG Volume (30 Days)
- ACAD 2.3M
- PHI 127.6K
- Earning Date
- ACAD 11-05-2025
- PHI 11-11-2025
- Dividend Yield
- ACAD N/A
- PHI 6.38%
- EPS Growth
- ACAD 615.00
- PHI 20.57
- EPS
- ACAD 1.33
- PHI 2.62
- Revenue
- ACAD $1,018,885,000.00
- PHI $3,879,170,293.00
- Revenue This Year
- ACAD $14.01
- PHI $3.27
- Revenue Next Year
- ACAD $11.81
- PHI $3.07
- P/E Ratio
- ACAD $16.07
- PHI $7.28
- Revenue Growth
- ACAD 14.41
- PHI 2.02
- 52 Week Low
- ACAD $13.40
- PHI $18.61
- 52 Week High
- ACAD $26.65
- PHI $27.39
- Technical
- Relative Strength Index (RSI)
- ACAD 33.94
- PHI N/A
- Support Level
- ACAD $21.32
- PHI N/A
- Resistance Level
- ACAD $21.96
- PHI N/A
- Average True Range (ATR)
- ACAD 0.60
- PHI 0.00
- MACD
- ACAD -0.10
- PHI 0.00
- Stochastic Oscillator
- ACAD 30.11
- PHI 0.00
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About PHI PLDT Inc. Sponsored ADR
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.